<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">16114982</PMID>
      <DateCompleted>
        <Year>2005</Year>
        <Month>11</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>11</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0012-6667</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>65</Volume>
            <Issue>13</Issue>
            <PubDate>
              <Year>2005</Year>
            </PubDate>
          </JournalIssue>
          <Title>Drugs</Title>
          <ISOAbbreviation>Drugs</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Ramipril/felodipine extended-release fixed-dose combination: a review of its use in the management of essential hypertension.</ArticleTitle>
        <Pagination>
          <StartPage>1851</StartPage>
          <EndPage>1868</EndPage>
          <MedlinePgn>1851-68</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Ramipril/felodipine extended release (ER) [Triapin and Triapin Mite, Unimax] is a once-daily fixed-dose combination of the ACE inhibitor ramipril and the ER formulation of the dihydropyridine calcium channel antagonist felodipine. It is indicated in adult patients with essential hypertension whose blood pressure (BP) is inadequately controlled with ramipril or felodipine monotherapy. In this patient population, commercially available fixed-dose combinations (i.e. 2.5 mg/2.5 mg and 5 mg/5 mg) of ramipril and felodipine ER are more effective at controlling hypertension than the individual components used as monotherapy at the same dosages. Likewise, the 5 mg/5 mg combination is as effective as felodipine ER 10 mg, and more effective than ramipril 10 mg administered as monotherapy. The addition of low-dose ramipril plus felodipine ER (fixed-dose or combination of individual components) to the existing antihypertensive regimen also appears to provide adequate BP control and renal protection in hypertensive patients with non-diabetic chronic renal disease. In these patients, the low-dose combination of ramipril and felodipine ER was as effective as standard-dose felodipine ER, but more effective than standard-dose ramipril, in providing diastolic BP (DBP) control, and as effective as standard-dose ramipril, but more effective than standard-dose felodipine ER, in slowing the rate of regression of glomerular filtration. The ramipril/felodipine ER combination is as well tolerated as ramipril or felodipine ER monotherapy administered at the same dosages, and is better tolerated than felodipine ER monotherapy given at twice the dosage used in the combination. Overall, ramipril/felodipine ER appears to be an effective option for the treatment of adults with essential hypertension that is poorly controlled with monotherapy. In addition, a fixed, low-dose combination of ramipril/felodipine ER is a potential alternative to monotherapy for the initial management of essential hypertension.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>CvetkoviÄ‡</LastName>
            <ForeName>Risto S</ForeName>
            <Initials>RS</Initials>
            <AffiliationInfo>
              <Affiliation>Adis International Limited, Auckland, New Zealand. demail@adis.co.nz</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Plosker</LastName>
            <ForeName>Greg L</ForeName>
            <Initials>GL</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>New Zealand</Country>
        <MedlineTA>Drugs</MedlineTA>
        <NlmUniqueID>7600076</NlmUniqueID>
        <ISSNLinking>0012-6667</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003692">Delayed-Action Preparations</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>L35JN3I7SJ</RegistryNumber>
          <NameOfSubstance UI="D017257">Ramipril</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>OL961R6O2C</RegistryNumber>
          <NameOfSubstance UI="D015736">Felodipine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003692" MajorTopicYN="N">Delayed-Action Preparations</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015736" MajorTopicYN="N">Felodipine</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017257" MajorTopicYN="N">Ramipril</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051437" MajorTopicYN="N">Renal Insufficiency</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <NumberOfReferences>49</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2005</Year>
          <Month>8</Month>
          <Day>24</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2005</Year>
          <Month>12</Month>
          <Day>13</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2005</Year>
          <Month>8</Month>
          <Day>24</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">16114982</ArticleId>
        <ArticleId IdType="doi">10.2165/00003495-200565130-00009</ArticleId>
        <ArticleId IdType="pii">65139</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Eur Heart J. 2004 Aug;25(16):1454-70</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15302105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>JAMA. 2003 May 14;289(18):2363-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12746359</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>N Engl J Med. 2000 Jan 20;342(3):145-53</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10639539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Pharmacol Ther. 1995 May;57(5):569-81</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7768080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drugs. 1992 Aug;44(2):251-77</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1382018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drugs Aging. 1992 Sep-Oct;2(5):374-88</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1392220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hypertension. 2004 Jan;43(1):10-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14638619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Hum Hypertens. 1990 Dec;4(6):703-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2151392</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>JAMA. 1996 May 15;275(19):1507-13</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8622227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drugs. 1990 Jan;39(1):110-35</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2138076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Hypertens. 2003 Jun;21(6):1011-53</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12777938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scand J Clin Lab Invest. 1997 Dec;57(8):673-81</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9458489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>JAMA. 2002 Dec 18;288(23):2981-97</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12479763</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Am J Hypertens. 1999 Aug;12(8 Pt 2):86S-90S</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10478702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Curr Med Res Opin. 1996;13(8):445-56</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9010611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Exp Hypertens. 1999 Nov;21(8):1447-62</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10574423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nephrol Dial Transplant. 2001 Nov;16(11):2158-65</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11682661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Hypertens. 1995 Nov;13(11):1325-34</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8984131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Am J Hypertens. 1999 Aug;12(8 Pt 2):73S-79S</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10478700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drugs. 1995 Mar;49(3):440-66</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7774515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>BMJ. 2004 Mar 13;328(7440):634-40</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15016698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drug Saf. 1998 Apr;18(4):251-72</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9565737</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Am Coll Cardiol. 2005 Mar 15;45(6):813-27</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15766813</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lancet. 2005 Mar 12-18;365(9463):939-46</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15766995</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lancet. 1998 Jun 13;351(9118):1755-62</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9635947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>JAMA. 2002 Dec 18;288(23):3039-42</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12479770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pharmacoeconomics. 2004;22(15):955-73</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15449961</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Hypertens Suppl. 1998 Oct;16(6):S29-34</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9856381</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Intern Med J. 2003 Sep-Oct;33(9-10):414-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14511193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Am Coll Cardiol. 2004 Jun 16;43(12 ):2200-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15193680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lancet. 2002 Nov 2;360(9343):1347-60</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12423980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blood Press. 1996 Sep;5(5):285-91</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8879601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drugs. 2002;62(3):443-62</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11827559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Pharmacokinet. 1998 Jun;34(6):457-82</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9646008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Br J Clin Pharmacol. 1991 Feb;31(2):148-53</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1646621</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>JAMA. 2003 May 21;289(19):2560-72</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12748199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nephrol Dial Transplant. 1998 Mar;13(3):564-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9550628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Hypertens. 2003 Nov;21(11):1983-92</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14597836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drugs. 2002;62(9):1381-405</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12076194</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
